| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0090-4295(89)90440-8 |
| P698 | PubMed publication ID | 2595880 |
| P2093 | author name string | C A Olsson | |
| I S Sawczuk | |||
| J P Connor | |||
| M C Benson | |||
| F Rapoport | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| vinblastine | Q282629 | ||
| transitional cell carcinoma | Q2501186 | ||
| cisplatin | Q412415 | ||
| methotrexate | Q422232 | ||
| P304 | page(s) | 353-356 | |
| P577 | publication date | 1989-12-01 | |
| P1433 | published in | Urology | Q7900884 |
| P1476 | title | Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern | |
| P478 | volume | 34 |
| Q33361999 | A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. |
| Q52873284 | A phase II study of epirubicin in advanced transitional cell bladder cancer. The Yorkshire Urological Cancer Research Group. |
| Q35981922 | Chemotherapy for advanced bladder cancer: 'Midsummer Night's Dream' or 'Much Ado About Nothing'? |
| Q35076309 | Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy |
| Q36622949 | Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer |
| Q33978838 | Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer |
| Q77952069 | Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer |
| Q33382500 | Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy |
| Q33978854 | Gemcitabine and paclitaxel combination therapy in transitional cell carcinoma of the urothelium |
| Q33332660 | Gemcitabine in locally advanced and/or metastatic bladder cancer |
| Q33567204 | Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer |
| Q41483381 | Metastatic bladder cancer: advances in treatment |
| Q41465688 | New approaches in the treatment of metastatic transitional-cell cancer of the bladder |
| Q33844443 | The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and induces apoptosis of urothelial cancer cells. |
| Q60049823 | The continuing role of chemotherapy in the management of advanced urothelial cancer |
| Q33394213 | The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen |
| Q83177250 | The role of neoadjuvant or adjuvant chemotherapy for invasive bladder cancer Is there a benefit for survival or preserving the bladder? |
| Q35193683 | The systemic treatment of advanced and metastatic bladder cancer. |
Search more.